2020 CAP临床指南:乳腺癌雌激素和孕激素受体检测

2020-01-13 美国病理学家协会 Arch Pathol Lab Med. 2020 Jan 13.

2020年1月,美国临床肿瘤学会(ASCO)联合美国病理学家协会(CAP)发布了乳腺癌雌激素和孕激素受体检测指南,本文是对前一版指南推荐意见的更新,共针对4个临床问题提出指导建议。

中文标题:

2020 CAP临床指南:乳腺癌雌激素和孕激素受体检测

英文标题:

Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.

发布机构:

美国病理学家协会

发布日期:

2020-01-13

简要介绍:

2020年1月,美国临床肿瘤学会(ASCO)联合美国病理学家协会(CAP)发布了乳腺癌雌激素和孕激素受体检测指南,本文是对前一版指南推荐意见的更新,共针对4个临床问题提出指导建议。

 

拓展指南:乳腺癌相关指南:

相关资料下载:
[AttachmentFileName(sort=100, fileName=2020 CAP临床指南:乳腺癌雌激素和孕激素受体检测)] GetToolGuiderByIdResponse(projectId=1, id=6361d1c0018561d3, title=2020 CAP临床指南:乳腺癌雌激素和孕激素受体检测, enTitle=Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update., guiderFrom=Arch Pathol Lab Med. 2020 Jan 13., authorId=null, author=, summary=2020年1月,美国临床肿瘤学会(ASCO)联合美国病理学家协会(CAP)发布了乳腺癌雌激素和孕激素受体检测指南,本文是对前一版指南推荐意见的更新,共针对4个临床问题提出指导建议。 , cover=, journalId=null, articlesId=null, associationId=107, associationName=美国病理学家协会, associationIntro=美国病理学家协会(CAP,College of American Pathologists)是美国一个非赢利的临床实验室认可机构,它依据美国临床检验标准化委员会(CLSI)的业务标准和操作指南,以及1988年的美国临床实验室改进规范(CLIA&rsquo;88),对临床实验室各个学科的所有方面均制定了详细的检查单,通过严格要求来确保实验室符合质量标准,从而改进实验室的实际工作。CAP致力于临床试验室步骤的标准化和改进;倡导高质量和经济有效的医疗保健服务,其所产生的影响超过了其他任何一个组织,因此被国际公认为是实验室质量保证的领导者和权威性的实验室管理和认证组织。, copyright=0, guiderPublishedTime=Mon Jan 13 00:00:00 CST 2020, originalUrl=, linkOutUrl=, content=<P>2020年1月,美国临床肿瘤学会(ASCO)联合美国病理学家协会(CAP)发布了乳腺癌雌激素和孕激素受体检测指南,本文是对前一版指南推荐意见的更新,共针对4个临床问题提出指导建议。 </P> <P> </P>拓展指南:<strong>与<font color=red>乳腺癌</font>相关指南:</strong><br><ul><li><a href="https://www.medsci.cn/guideline/show_article.do?id=8b5bb1c001853a9f" title="NCCN临床实践指南:乳腺癌(2020.V1)" target=_blank>NCCN临床实践指南:乳腺癌(2020.V1)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=319f11c001850237" title="中国乳腺癌靶向治疗药物安全性管理专家共识" target=_blank>中国乳腺癌靶向治疗药物安全性管理专家共识</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=6403f1c0018a43a7" title="复发/转移性乳腺癌标志物临床应用专家共识(2019年版)" target=_blank>复发/转移性乳腺癌标志物临床应用专家共识(2019年版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=5248d1c001839152" title="乳腺癌术后乳房重建中国专家共识(2019版)" target=_blank>乳腺癌术后乳房重建中国专家共识(2019版)</a></li> <li><a href="https://www.medsci.cn/guideline/show_article.do?id=0c1dd1c00183084c" title="2018 JBCS临床实践指南:乳腺癌的筛查和诊断" target=_blank>2018 JBCS临床实践指南:乳腺癌的筛查和诊断</a></li> 更多信息请点击:<a href="https://www.medsci.cn/guideline/list.do?q=%E4%B9%B3%E8%85%BA%E7%99%8C" target=_blank>有关乳腺癌更多指南</a></ul>, tagList=[TagDto(tagId=285, tagName=乳腺癌), TagDto(tagId=99071, tagName=雌激素受体检测), TagDto(tagId=99072, tagName=孕激素受体检测)], categoryList=[CategoryDto(categoryId=5, categoryName=肿瘤科, tenant=100), CategoryDto(categoryId=89, categoryName=乳腺癌, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=null, articleKeyword=null, articleKeywordNum=null, guiderKeywordId=null, guiderKeyword=null, guiderKeywordNum=null, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=0, guiderRegion=0, opened=0, paymentType=null, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=14557, appHits=248, showAppHits=44, pcHits=3023, showPcHits=13146, likes=46, shares=5, comments=4, approvalStatus=1, publishedTime=Mon Jan 27 20:06:26 CST 2020, publishedTimeString=2020-01-13, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=1, createdBy=null, createdName=qiushida2, createdTime=Mon Jan 27 20:06:26 CST 2020, updatedBy=null, updatedName=null, updatedTime=Thu Jan 04 08:06:56 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=100, fileName=2020 CAP临床指南:乳腺癌雌激素和孕激素受体检测)])
2020 CAP临床指南:乳腺癌雌激素和孕激素受体检测
下载请点击:
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=917459, encodeId=d01d91e45955, content=需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210117/c2b8e66ba657457085a2b0716bc9a6f6/2b3ebdd558694078a7c0739d39a130f2.jpg, createdBy=2e895453017, createdName=ms1000001851298786, createdTime=Sun Jan 17 13:51:32 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893043, encodeId=55998930430b, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210202/b6e581be368a46b08d225d5c467a6a89/f7091bf50539458b9ebc0dd9e0ae1937.jpg, createdBy=9e1d5318884, createdName=148a3cb9m62(暂无昵称), createdTime=Mon Oct 19 15:04:56 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880828, encodeId=d5dc88082836, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Aug 30 10:04:22 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2021-01-17 ms1000001851298786

    需要

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=917459, encodeId=d01d91e45955, content=需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210117/c2b8e66ba657457085a2b0716bc9a6f6/2b3ebdd558694078a7c0739d39a130f2.jpg, createdBy=2e895453017, createdName=ms1000001851298786, createdTime=Sun Jan 17 13:51:32 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893043, encodeId=55998930430b, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210202/b6e581be368a46b08d225d5c467a6a89/f7091bf50539458b9ebc0dd9e0ae1937.jpg, createdBy=9e1d5318884, createdName=148a3cb9m62(暂无昵称), createdTime=Mon Oct 19 15:04:56 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880828, encodeId=d5dc88082836, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Aug 30 10:04:22 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2020-10-19 148a3cb9m62(暂无昵称)

    很好

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=917459, encodeId=d01d91e45955, content=需要, beContent=null, objectType=guider, channel=null, level=null, likeNumber=83, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210117/c2b8e66ba657457085a2b0716bc9a6f6/2b3ebdd558694078a7c0739d39a130f2.jpg, createdBy=2e895453017, createdName=ms1000001851298786, createdTime=Sun Jan 17 13:51:32 CST 2021, time=2021-01-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=893043, encodeId=55998930430b, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=107, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210202/b6e581be368a46b08d225d5c467a6a89/f7091bf50539458b9ebc0dd9e0ae1937.jpg, createdBy=9e1d5318884, createdName=148a3cb9m62(暂无昵称), createdTime=Mon Oct 19 15:04:56 CST 2020, time=2020-10-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=880828, encodeId=d5dc88082836, content=很好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=99, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b4ab2205971, createdName=120c570cm03暂无昵称, createdTime=Sun Aug 30 10:04:22 CST 2020, time=2020-08-30, status=1, ipAttribution=)]
    2020-08-30 120c570cm03暂无昵称

    很好

    0